Results 221 to 230 of about 15,451 (255)

Trends in Early‐Onset Cancer Incidence Rates in Latin America: A Scoping Review Protocol

open access: yesHealth Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background/Aims The global incidence of early‐onset (EO) cancers—defined as malignancies diagnosed in individuals under the age of 50—has increased significantly over recent decades, particularly in high‐income countries. However, epidemiological data from Latin America remain fragmented and underexplored.
Vitor Fiorin Vasconcellos   +13 more
wiley   +1 more source

Graded chronic noncancer pain distribution using the Graded Chronic Pain Scale-Revised framework: a cross-sectional study. [PDF]

open access: yesPain Rep
Hellmann SS   +7 more
europepmc   +1 more source

Mediating Effect of Anxiety/Depression Between Nomophobia and Disordered Eating Among Lebanese Young Adults: A Cross‐Sectional Study

open access: yesHealth Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Aims Disordered eating is characterized by abnormal eating habits leading to negative health effects. The goal of this study was to assess the mediating effect of depression and anxiety between nomophobia and disordered eating among a sample of Lebanese young adults.
Elie Kesrewani   +7 more
wiley   +1 more source

In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug‐Metabolizing Enzymes

open access: yesThe Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Bemnifosbuvir is a novel oral guanosine nucleotide prodrug with potent pan‐genotypic inhibitory activity against hepatitis C virus. In vitro studies assessing the inhibition or induction potential of bemnifosbuvir on the CYP450 and UGT1A1 enzymes demonstrated that bemnifosbuvir is a weak inducer and a reversible and time‐dependent inhibitor of
Xiao‐Jian Zhou   +10 more
wiley   +1 more source

The Effect of Iclepertin on Hematological Parameters: An Overview of Nonclinical Studies and Clinical Trials in Healthy Volunteers and Patients with Cognitive Impairment Associated with Schizophrenia

open access: yesThe Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract There are currently no approved pharmacotherapies to treat cognitive impairment associated with schizophrenia (CIAS). Iclepertin (BI 425809) is a selective glycine transporter‐1 (GlyT1) inhibitor that was investigated for the treatment of CIAS.
Peter Nagy   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy